SCHEMBL25758817

SCHEMBL25758817

COc1ccc2[nH]c(C(=O)NC(C)C)cc2c1Cl

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.54
MEN1 O00255 6/20 0.54
RCE1 Q9Y256 1/20 0.54
ALOX15 P16050 1/20 0.53
MAPT P10636 7/20 0.44
ALDH1A1 P00352 4/20 0.44
POLB P06746 2/20 0.44
LMNA P02545 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
HPGD P15428 1/20 0.44
PTBP1 P26599 1/20 0.44
KDM4E B2RXH2 5/20 0.44
BLM P54132 1/20 0.43
TLR9 Q9NR96 1/20 0.42
TLR8 Q9NR97 1/20 0.42
TLR7 Q9NYK1 1/20 0.42
RAB9A P51151 2/20 0.42
NPC1 O15118 1/20 0.42
TAS1R3 Q7RTX0 2/20 0.41
TAS1R1 Q7RTX1 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24740396 0.85 ALOX15 (0.57) KMT2AMEN1RCE1ALOX15MAPT
SCHEMBL19330914 0.83 GLA (0.47) KMT2AMEN1MAPTALDH1A1POLB
SCHEMBL30310487 0.83 GLA (0.47) KMT2AMEN1MAPTALDH1A1POLB
SCHEMBL24740418 0.83 ALOX15 (0.52) KMT2AMEN1RCE1ALOX15MAPT
SCHEMBL25758815 0.83 ALOX15 (0.58) KMT2AMEN1RCE1ALOX15MAPT
SCHEMBL30310573 0.82 KDM4E (0.59) KMT2AMEN1ALDH1A1LMNAHPGD
SCHEMBL3110626 0.82 KDM4E (0.59) KMT2AMEN1ALDH1A1LMNAHPGD
SCHEMBL24028985 0.82 ALOX15 (0.53) KMT2AMEN1RCE1ALOX15MAPT
SCHEMBL23836099 0.81 KMT2A (0.77) KMT2AMEN1RCE1MAPTPOLB
SCHEMBL29063128 0.81 RHEB (0.47) KMT2AMEN1RCE1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-07-06 US disclosed
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTRL, CTSL, CTSV KMT2A 3383/4885MEN1 4306/4885RCE1 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.